Shenzhen Hepalink Pharma closed a $13 million investment in OncoQuest, the oncology subsidiary of Canada's Quest PharmaTech Inc., giving Hepalink a 42% stake in OncoQuest. OncoQuest is developing several immunotherapeutic antibodies to treat cancer. The two companies are also reported to be in talks on a $5 million JV to develop OncoQuest's products in China. Hepalink is major global supplier of heparin API.
